Articles tagged with Prostate Cancer
A novel PET tracer, Carbon-11 labeled sarcosine (11C-sarcosine), demonstrates potential for imaging prostate cancer. The tracer shows elevated tumor-to-background ratios and high-contrast images in human cases, suggesting its viability as a replacement for existing tracers.
Men who are tall and obese have an increased risk of high grade prostate cancer and death from prostate cancer, according to a study published in BMC Medicine. The research found that height is not associated with overall prostate cancer risk but increases the risk of high grade disease and death by 21% and 17% respectively.
A 20-year study found that surgery for early-stage prostate cancer did not prolong life and often caused serious complications. Most men with early prostate cancer are more likely to survive with limited or no treatment.
Elena Castro, a Spanish researcher, is awarded the Prostate Cancer Foundation's Young Investigator Award for her project on DNA damage repair genes and their impact on advanced prostate cancer progression. The award supports her work to develop therapeutic strategies for patients with genetic defects.
Research found that genes responsible for differential RNA splicing contribute to tumor aggressiveness and drug resistance in African American men with prostate cancer. The study suggests these genetic variations lead to the production of protein isoforms that make tumors more aggressive, while also causing drug resistance.
A study published in Cell Chemical Biology highlights the need for new treatment approaches for treatment-resistant prostate cancer. Researchers found that effective steroidal anti-androgens share common metabolic activities, suggesting a potential strategy to improve efficacy.
A new three-in-one blood test developed by researchers at the Institute of Cancer Research can pick out men with advanced prostate cancer who are likely to benefit from treatment with PARP inhibitors. The test detects early signs of resistance and monitors cancer's evolution over time, allowing for timely adjustments to treatment.
Researchers demonstrate preclinically that dual-labeled PSMA-inhibitors improve preoperative staging and intra-operative guidance for metastatic prostate cancer patients. This combined approach results in more accurate detection of PSMA-positive tumor lesions, enhancing patient outcomes.
A new imaging test, Ga-68 PSMA PET/CT, has been shown to detect cancer that conventional imaging missed, changing treatment plans for 51% of patients. The test also improved management for patients with recurrent disease, with 69% receiving radiation therapy and 64% undergoing surgery.
Researchers at H. Lee Moffitt Cancer Center identify novel inhibitor (R)-9bMS that targets epigenetic modification of the androgen receptor gene, blocking growth in resistant prostate cancer cells. The discovery offers a new therapeutic option for castration-resistant prostate cancer patients who do not respond to enzalutamide.
Researchers demonstrated the efficacy of targeted photodynamic therapy (tPDT) to treat prostate cancer before and during surgery, using a PSMA-targeting agent coupled with photosensitizers. The technique optimizes prostate cancer care by allowing visualization of tumors prior to surgery and providing real-time guidance to surgeons.
The EV-FPS test correctly identifies men with aggressive prostate cancer 40% more accurately than current PSA tests. It has the potential to eliminate up to 600-thousand unnecessary biopsies and reduce hospitalizations annually in North America.
Researchers at the University of Texas at Austin identified several plant-based compounds that can prevent or slow down prostate cancer growth. The study found that combining these compounds, such as ursolic acid and curcumin, with glutamine can block the nutrient uptake needed by prostate cancer cells.
A study found that black men are more concerned about the impact of treatment on their daily lives, recovery time, and cost, while white men prioritize quality of life and cancer cure. These differences in perceptions may contribute to racial disparities in prostate cancer treatment.
Adding abiraterone acetate to standard hormonal therapy reduces the chance of death by 38% and doubles the median time until cancer worsens. Cancer growth is delayed by 18 months, but severe side effects like high blood pressure and liver enzyme abnormalities are more common with abiraterone.
A clinical trial of nearly 2,000 men shows that adding abiraterone acetate to standard therapy for high-risk, advanced prostate cancer lowers the relative risk of death by 37% and increases the 3-year survival rate to 83%. The treatment also reduces the chance of relapse by 70% and serious bone complications by 50%.
The STAMPEDE trial found that adding abiraterone to standard hormone therapy improves prostate cancer survival in men with high-risk disease. The drug reduced disease progression by 70% and severe bone complications by more than half, leading to a 40% increase in overall survival.
Researchers are conducting a Phase 1 clinical trial using Lutetium 177Lu-PSMA-617 to target PSMA in men with progressive prostate cancer. The therapy aims to deliver precise radiation therapy and shrink the cancer, even in cases without visible tumors.
An educational session reduced pre-treatment distress in both prostate cancer patients and their partners, with sociodemographic and clinical characteristics having little impact on distress levels. The session was found to be equally effective for partners, emphasizing the need for targeted supportive care services for both individuals.
Researchers found that using MRI to detect lesions and guide biopsies increased standardized quality-adjusted life years for patients, and was cost-effective in 94.05% of simulations. This approach could change how doctors identify and sample cancer lesions, reducing unnecessary treatments and costs.
Researchers have developed a new blood test called IsoPSA that detects prostate cancer more accurately than current tests. The study found that IsoPSA can distinguish cancer from benign conditions and identify patients with high-risk disease, potentially reducing the need for unnecessary biopsies.
A Penn study has identified a new molecular chain of events that highlights novel targets to treat prostate cancer, which also shows promise in treating lung cancer. The research found that PKCε overexpression can cause cancer progression and that blocking CXCL13-CXCR5 molecules may be a new cancer treatment.
A new study found that treating prostate cancer with a single high dose of precise radiation results in fewer hospital trips, lower toxicity, and improved quality of life compared to traditional treatments. Patients reported high satisfaction with the convenient outpatient procedure.
Researchers discovered that tumor cells in patients with advanced prostate cancer are reprogrammed, reducing response to anti-androgen therapy and creating more aggressive tumors. SOX11 acts as a key regulator in this process, which may be targeted for new treatments.
A new blood test can detect multiple copies of the androgen receptor gene in men with advanced prostate cancer, indicating a lower likelihood of responding to targeted treatments. The test could help doctors personalize treatment options for patients.
Researchers at Duke University discovered that CYP17A1 inhibitors function as competitive AR antagonists, indicating a more effective role in treating prostate cancer. The study found that these inhibitors can inhibit the growth of prostate tumor cells expressing treatment-resistant AR mutations.
A study of 7,000 Italian men found that drinking more than three cups of Italian-style coffee per day reduces prostate cancer risk by over 50%. Laboratory tests confirmed the protective effect of caffeine in reducing cancer cell proliferation and metastasis.
A new biopsy technique combining MRI and ultrasound improves prostate cancer detection. Researchers found that patients are willing to pay $1,598 more for a biopsy increasing the likelihood of detecting all types of prostate cancer from 43% to 51%.
Black men in the US are at a higher risk of developing preclinical prostate cancer and having it progress quickly to advanced stages. Screening policies may need to be tailored to their higher-risk status.
A new study by the American Cancer Society found that prostate specific antigen (PSA) testing rates among men 50 years or older have leveled off at 32.1%. This trend is notable given previous declines in PSA screening rates, which dropped from 37.8% in 2010 to 30.8% in 2013.
The study found that sexual function declined after all treatments, with robotic surgery patients regaining function closest to brachytherapy and radiation levels. Urinary incontinence also decreased most for surgical patients, with robotic surgery showing slight improvement over open surgery.
Researchers demonstrate that an aggressive combination of systemic therapy and local therapy can eliminate all detectable disease in selected patients with metastatic prostate cancer. One-fifth of the patients treated had no detectable disease, with undetectable PSA and normal testosterone levels after 20 months.
A recent review suggests that a family history of prostate cancer does not increase the risk of more aggressive cancer progression. Men with a family history should discuss risks and options with their doctor, and further research is needed to confirm these findings, particularly among African American men.
A clinical trial found that twice-weekly yoga led to better physical, sexual, emotional, and social health in men with prostate cancer. Patients who practiced yoga reported lower fatigue and improved urinary function compared to those without yoga.
Researchers at the University of Missouri have discovered a new biomarker, TSPYL5, that can help identify prostate cancer progression and predict treatment response. The testis-specific protein varied between normal patients and tumor tissues with different Gleason scores, allowing clinicians to make rational decisions in treating the ...
The study found that E4 lowered testosterone levels in healthy male volunteers, with decreasing total and free testosterone, FSH, and estradiol levels. The hormone was well-tolerated, with only libido decrease and nipple tenderness reported.
Researchers have identified a set of molecules in urine that are present in 90% of prostate cancer patients but not in healthy individuals. This discovery could lead to the development of a non-invasive test for early detection of prostate cancer, potentially reducing unnecessary biopsies and improving patient outcomes.
Researchers have developed selective androgen receptor degraders (SARDs) that can degrade all forms of the androgen receptor, potentially providing advanced treatment options for men with castration-resistant prostate cancer. These molecules inhibit the growth of aggressive prostate cancers that are unresponsive to other treatments.
A new study reveals that only 30% of men in a national survey reported having a balanced discussion with their doctor about the advantages and disadvantages of prostate-specific antigen (PSA) testing. This trend has become less likely since the U.S. Preventive Services Task Force recommended against PSA testing in 2012.
The ASCO and Cancer Care Ontario have updated their clinical practice guideline on brachytherapy for patients with prostate cancer. The new guidelines recommend different treatment options for patients with varying risk levels, including low-risk, intermediate-risk, and high-risk prostate cancer. For eligible patients, brachytherapy is...
Researchers from Michigan Medicine have identified a novel strategy to target the genetic anomaly that occurs in half of all prostate cancers. They developed large molecule peptides that can effectively target and degrade the ERG fusion with little impact on regular cell function.
Two studies found that radical prostatectomy was associated with greater decreases in sexual function and urinary incontinence compared to active surveillance. However, no significant differences were found in bowel or hormonal function beyond 12 months.
A Vanderbilt University study found that active surveillance is a viable option for low-risk prostate cancer patients, preserving quality of life without significant side effects. The treatment was associated with excellent three-year survival rates and comparable outcomes to traditional treatments.
A new study has identified distinct patterns of side effects in prostate cancer treatment choices, providing insights for patients to make informed decisions. The research found that surgery was linked to higher sexual dysfunction and urinary leakage than other options.
Researchers at Washington State University developed a non-invasive filter-like device to isolate prostate cancer indicators from blood and urine, enabling doctors to track disease progression and treatment response. The technology uses biomarkers to capture tumor cells' genetic information, potentially predicting effective treatments.
Scientists identify a molecular pathway that enables prostate cancer cells to escape the primary tumor and form secondary tumors. This discovery holds promise for developing new therapeutic strategies to stop cancer cells from spreading, offering hope for improved treatment options for patients with metastatic prostate cancer.
Researchers at Oregon State University discovered that sulforaphane, a dietary compound from broccoli, may work by influencing long, non-coding RNAs. This finding suggests that these lncRNAs play a critical role in triggering cells to become malignant and spread.
A genetic connection to aggressive prostate cancer has been discovered, increasing the risk by threefold for men with a specific gene variant. The study's findings may lead to the development of a blood test to predict disease severity and aid in targeted treatment.
A WSU researcher has discovered that activated enzyme MAOA facilitates the spread of prostate cancer to bones by activating osteoclasts and enhancing bone degradation. Treatment targeting this enzyme shows promise in reducing bone metastasis.
Researchers at University of Alabama at Birmingham discovered endostatin's ability to decrease castration-resistant prostate cell growth in culture. Endostatin reduces oxidative stress and targets hormone receptors, shifting metabolism to scavenge reactive oxygen species.
Cabozantinib activates neutrophils, the first-responders of the immune system, to infiltrate tumor cells and trigger an immune response that leads to complete clearance of invasive prostate cancers. This innovative approach could lead to novel combination cancer immunotherapies.
Researchers found that Fluciclovine PET/CT significantly improved targeted therapy for recurrent prostate cancer by defining tumor-targeted areas. The treatment led to higher radiation doses to the penile bulb without increased toxicity.
Researchers developed a new framework to classify human prostate cancer using mathematical approach Latent Process Decomposition (LPD), identifying a novel 'poor prognosis' category called DESNT. This distinction helps target therapy to men with significant cancers, avoiding unnecessary treatments and side effects.
A novel mutation in the DNA repair protein ALKBH7 has been associated with an increased risk of prostate cancer in African American men. The study's findings suggest that this mutation may interfere with the protein's normal activity, leading to reduced ability to repair DNA damage.
Researchers found that a shorter course of radiation therapy, known as moderate hypofractionation, is just as effective at treating prostate cancer while costing less. This approach can help patients recover more quickly and reduces the burden on treatment centers and payers.
Prostate cancer cells grow with malfunction of cholesterol control in cells, a process that allows them to accumulate fat and stimulate uncontrolled growth. Identifying this process could inform the development of better ways to control cholesterol accumulation in tumors.
Researchers developed a novel biofunctionalized silica nanostructure to selectively capture tumor-derived exosomes bearing the PSMA biomarker, overcoming limitations of alternative approaches. The technology enables non-invasive diagnosis and prognosis of prostate cancer with high recovery yields and improved efficiency.
Researchers at Cold Spring Harbor Laboratory have discovered that Importin-11 protects the anti-cancer protein PTEN from degradation by transporting it into the cell nucleus. This discovery suggests that the loss of Importin-11 may destabilize PTEN, leading to cancer development in lung, prostate, and other cancers.
A study by Cold Spring Harbor Laboratory researchers found that Importin-11 protects the anti-cancer protein PTEN from destruction, leading to cancer progression. Loss of Importin-11 may destabilize PTEN, predicting disease relapse and metastasis in prostate cancer patients.
A study found that taking abiraterone acetate, a widely used prostate cancer drug, with a low-fat breakfast is as effective as taking it on an empty stomach, but at a significantly lower cost. The finding could save patients thousands of dollars per month.